ProCE Banner Activity

ADJUVANT: Phase III Trial Evaluating Gefitinib vs Vinorelbine/Cisplatin in Completely Resected Stage II-IIIA (N1-N2) NSCLC With EGFR Activating Mutations

Slideset Download
Conference Coverage
Adjuvant gefitinib for up to 2 years achieved superior DFS vs vinorelbine/cisplatin with no cases of interstitial lung disease.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology